Amo Pharma Ltd company information, Employees & Contact Information

AMO Pharma Reports Long-Term Safety Data from REACHCDM-X Study of AMO-02 in Treatment of Congenital Myotonic Dystrophy Type 1 PR Newswire

AMO Pharma, PHRI Team Up to Advance ARVC Study Diagnostic and Interventional Cardiology

AMO Pharma to conduct Phase III trial of DM1 treatment Clinical Trials Arena

Despite Failing to Meet Primary End Point, AMO-02 Shows Additional Benefits in Myotonic Dystrophy NeurologyLive

AMO Pharma to start AMO-02 Phase 3 trial in adult-onset DM1 Muscular Dystrophy News

Companies To Watch: AMO Pharma Life Science Leader

AMO Pharma Addresses Rare Childhood Disease Clinical Leader

Fast Track Status Granted to Tideglusib for Myotonic Dystrophy Medical Professionals Reference

AMO Pharma receives FDA Fast Track Status European Biotechnology Magazine

AMO Pharma Announces Collaboration with Population Health Research Institute to Advance Proof of Concept Clinical Trial to Assess Efficacy of Tideglusib in Treatment of Arrhythmogenic Cardiomyopathy Diagnostic and Interventional Cardiology

Phase 3 Trial for Myotonic Dystrophy Agent AMO-02 To Begin Following FDA Meeting NeurologyLive

AMO Pharma Announces Affirming Data from REACH-CDM Clinical Trial for AMO-02 in Treatment of Myotonic Dystrophy PR Newswire

AMO Pharma’s Myotonic Dystrophy Therapy Improves Cognition and Function, Phase 2 Trial Shows Muscular Dystrophy News

Assessing Phase 2/3 Trial Safety and Efficacy of AMO-02 for Myotonic Dystrophy: Mike Snape, PhD NeurologyLive

AMO Pharma Completes Meeting with U.S. FDA and Outlines Plans to Advance Clinical Development of AMO-02 (tideglusib) in Treatment of Myotonic Dystrophy PR Newswire

Oral AMO-02 aids muscle, heart health in mouse model of DMD |... Muscular Dystrophy News

AMO Pharma Announces Collaboration with Population Health Research Institute to Advance Proof of Concept Clinical Trial to Assess Efficacy of Tideglusib in Treatment of Arrhythmogenic Cardiomyopathy PR Newswire

Tideglusib Improves Myotonic Dystrophy Type 1 Neuromuscular Symptoms NeurologyLive

Myotonic Dystrophy Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight Yahoo Finance

FDA lifts clinical hold on Avidity’s lead antibody conjugate therapy trial Clinical Trials Arena

Del-desiran for DM1 wins FDA’s breakthrough therapy designation Muscular Dystrophy News

Gene therapy improves functional outcomes for boys with Duchenne muscular dystrophy Healio

Vertex pays Entrada $224M for preclinical rare disease drug, opening new front in assault on dystrophy Fierce Biotech

CMI Media Group’s Empower™ OS Solves for Media Fragmentation Challenges to Health Brands Fierce Pharma

New Treatment in Pipeline for Patients with Hypertrophic Cardiomyopathy Diagnostic and Interventional Cardiology

Lilly to Acquire Versanis to Improve Patient Outcomes in Cardiometabolic Diseases Diagnostic and Interventional Cardiology

Myotonic Dystrophy Pipeline Assessment Report 2025: Emerging openPR.com

FDA Receives Resubmission of the Apixaban Drug Application to Reduce Stroke in Patients With Atrial Fibrillation Diagnostic and Interventional Cardiology

Baxter International Acquires Prism Pharmaceuticals Diagnostic and Interventional Cardiology

United States Rett Syndrome Market Driven by Rising Gene Therapy openPR.com

Resverglogix Study Examines Atherosclerotic Plaque Regression Drug Diagnostic and Interventional Cardiology

FDA Approves Tekturna HCT to Treat Patients With High Blood Pressure Diagnostic and Interventional Cardiology

Acceleron Receives FDA Fast Track Designation for ACE-083 in Facioscapulohumeral Muscular Dystrophy (FSHD) drugdiscoverytrends.com

New Dosage Strengths Sought for Cholesterol-Lowering Medication Diagnostic and Interventional Cardiology

Drug Offers Different Way to Fight Cholesterol Diagnostic and Interventional Cardiology

Intravenous Drug Treats Dyspnea in Heart Failure Patients Diagnostic and Interventional Cardiology

Hypersonic engines to AI, four of Schroders Capital's top private equity positions Citywire

FDA Approves Stroke Prevention Drug in Atrial Fibrillation Patients Diagnostic and Interventional Cardiology

FDA Warns Obesity Drug May Increase Cardiovascular Events Diagnostic and Interventional Cardiology

American College of Cardiology Develops Statin Intolerance App Diagnostic and Interventional Cardiology

Merck, Schering-Plough Resolve Civil Class-Action Lawsuits Related to VYTORIN, ZETIA Diagnostic and Interventional Cardiology

Rett Syndrome Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2023-2032), | DelveInsight | Prilenia Therapeutics, GEXVal, Neurogene Inc, Taysha Gene Therapies, Vyant Bio The Globe and Mail

FDA Warns PPIs Impact Effectiveness of Clopidogrel Diagnostic and Interventional Cardiology

Neil Woodford touts for institutional investors with details of eight-stock biotech portfolio Portfolio Adviser